Latest Macular degeneration Stories
New CEO to Lead Market Expansion of Novel Treatment for Advanced Macular Degeneration SARATOGA, Calif., April 15, 2015 /PRNewswire/ -- VisionCare Ophthalmic Technologies ("VisionCare"),
LONDON, April 6, 2015 /PRNewswire/ -- Report DetailsAnalysis of revenues and R&D prospects for those eye drugs - you explore potentialsWhat's the future for treating disorders
Efficacy and Safety of Long-term, Continuous Anti-VEGF will be Assessed in Phase 2 Study CUMBERLAND, R.I., March 30, 2015 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc.
Market Publishers Ltd informs that new reports by GlobalData have been recently uploaded to its catalogue. London, UK (PRWEB) March 25, 2015 Market Publishers
LONDON, March 26, 2015 /PRNewswire/ -- Report Details Analysis of revenues and R&D prospects for those eye drugs - you explore potentials What's the future
Diabetic retinopathy in patients with DME is the fourth approved indication for EYLEA in the U.S. TARRYTOWN, N.Y., March 25, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Having good vision does not mean your eyes are healthy.
DALLAS, March 19, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Lucentis (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" market research
Biotech Veteran Will Lead Clinical Development Efforts of Encapsulated Cell Therapy in Ophthalmology CUMBERLAND, R.I., March 18, 2015 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc.
- The parings of haberdine; also, any kind of fragments.